Key Advances in Prostate, Kidney, and Bladder...

In part two of our miniseries on the global translation gap in oncology, host Dr. Monty Pal and Dr. Regina Barragán-Carrillo explore how ASCO26 Plenary breakthroughs can be adapted to clinical practice in Latin America. Together, they address real-world implementation challenges ...  Show more

Dr. Monty Pal and Dr. Rachna Shroff explore how GLP-1 receptor agonists impact progression and survival in GI cancers, examining current retrospective data, immune microenvironment biology, and the need for prospective trials. LINK TO FULL TRANSCRIPT 

Stay up-to-date on the latest advancements and treatment strategies in the field of genitourinary oncology. In this episode of BackTable Urology, guest host Dr. Bogdana Schmidt, a urologic oncologist from the University of Utah, discusses takeaways from ASCO 2024 with Dr. Petros ...  Show more

Neeraj Agarwal, MD, FASCO, describes the data from the TALAPRO-2 study on combination talazoparib and enzalutamide for metastatic castration-resistant prostate cancer as presented at the 2023 ASCO GU Cancers Symposium. Dr. Agarwal is a medical oncologist and Presidential Endow ...

The UROONCO RCC editorial board chief editor Dr. Carmen Mir, and associate editors Dr. Teele Kuusk and Dr. Riccardo Bertolo share highlights of the important kidney cancer developments for 2024. 

They summarise the results on several important trials such as FASTRACK, ...

Dr. Pedro Barata, Director of the Clinical Genitourinary Medical Oncology Research Program at UH Seidman Cancer Center, provides an exclusive round-up of the most groundbreaking and practice-changing research unveiled at the ASCO GU 2024 meeting. With expertise and insight, he de ...  Show more